Rhenman & Partners Asset Management AB Reduces Position in Eli Lilly and Company $LLY

Rhenman & Partners Asset Management AB lessened its position in Eli Lilly and Company (NYSE:LLY) by 21.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,220 shares of the company’s stock after selling 11,200 shares during the quarter. Eli Lilly and Company comprises about 4.2% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 2nd biggest position. Rhenman & Partners Asset Management AB’s holdings in Eli Lilly and Company were worth $45,373,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Beck Capital Management LLC raised its holdings in Eli Lilly and Company by 1.1% in the 4th quarter. Beck Capital Management LLC now owns 6,082 shares of the company’s stock worth $6,537,000 after acquiring an additional 64 shares during the period. Sumitomo Life Insurance Co. increased its holdings in shares of Eli Lilly and Company by 14.4% during the 4th quarter. Sumitomo Life Insurance Co. now owns 32,546 shares of the company’s stock worth $34,977,000 after purchasing an additional 4,087 shares during the period. Keystone Investors PTE Ltd. increased its holdings in shares of Eli Lilly and Company by 83.8% during the 4th quarter. Keystone Investors PTE Ltd. now owns 9,560 shares of the company’s stock worth $10,274,000 after purchasing an additional 4,360 shares during the period. Integrity Investment Advisors LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $297,000. Finally, Wealthspire Advisors LLC increased its holdings in shares of Eli Lilly and Company by 59.7% during the 4th quarter. Wealthspire Advisors LLC now owns 12,811 shares of the company’s stock worth $13,768,000 after purchasing an additional 4,787 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,137.01 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm’s 50-day simple moving average is $998.47 and its 200-day simple moving average is $1,016.72. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,182.73. The firm has a market cap of $1.07 trillion, a P/E ratio of 40.39, a price-to-earnings-growth ratio of 1.27 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period in the previous year, the business earned $3.34 EPS. The firm’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were given a $1.73 dividend. The ex-dividend date was Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on LLY shares. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday. Rothschild & Co Redburn boosted their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Wolfe Research restated an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Bank of America boosted their price objective on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and research notes continue to turn more upbeat on Eli Lilly’s earnings outlook, with Erste Group lifting FY2026 and FY2027 EPS estimates and Goldman Sachs reiterating a buy rating on the back of an encouraging obesity-treatment pipeline. Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline
• Positive Sentiment: Eli Lilly’s strong growth story is still resonating with investors: recent coverage says the stock is in a buy zone, institutional funds are adding shares, and the company remains a leader in the GLP-1 obesity market after a big earnings beat and raised guidance. Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.
• Positive Sentiment: The company also added a new growth angle by expanding its chronic pain pipeline, including new Phase 2 trials in osteoarthritis and chronic low back pain, which could broaden Lilly’s long-term revenue base beyond obesity and diabetes. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Positive Sentiment: FDA progress for Ebglyss, including an easier once-every-eight-weeks maintenance regimen, adds another commercial catalyst and supports Lilly’s push to diversify into dermatology. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Neutral Sentiment: Lilly also unveiled an AI partnership with Abridge, aimed at speeding drug development, trial enrollment and research; that is strategically positive, but it is a longer-term story than a near-term earnings driver. Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth
• Negative Sentiment: A key overhang is growing concern that some employers may reduce or drop coverage for GLP-1 weight-loss drugs in 2027, which could pressure demand and reimbursement for Lilly’s obesity franchise. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases 2026-06-11

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.